ACTR-67. PLASMA AND TUMOR PHARMACOKINETICS OF RIBOCICLIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Sign Up to like & getrecommendations! Published in 2017 at "Neuro-oncology"
DOI: 10.1093/neuonc/nox168.054
Abstract: BACKGROUND CDK4/6-dependent cell-cycle regulation is disrupted in 78% of glioblastoma (GBM) patients and novel CDK4/6 inhibitors have shown anti-tumor activity in animal models. To explore the utility of ribociclib, a selective CDK4/6-inhibitor, in treating recurrent… read more here.
Keywords: ribociclib patients; tumor pharmacokinetics; actr plasma; plasma tumor ... See more keywords